# US 2019/0167712 A1 · Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167712 A1
- Document ID: US20190167712A1
- Status: Published application
- Kind: A1
- Application number: 16/273,215
- Filed: 2019-02-12
- Published: 2019-06-06
- Earliest claimed: 2011-08-04
- Assignees: Yeda Research and Development Co. Ltd.
- Applicants: Yeda Research and Development Co. Ltd.
- Inventors: Alon CHEN; Eran HORNSTEIN; Orna ISSLER; Sharon HARAMATI; Naama VOLK
- Web page: https://patentgrep.com/patent/US20190167712A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 35/00: Antineoplastic agents
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12N 2310/141: MicroRNAs, miRNAs
- C12Q 2600/178: miRNA, siRNA or ncRNA
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

microRNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone-associated medical conditions are provided.

## Claims

### Claim 1

A method of treating a medical condition in which a low glutamate receptor level is therapeutically beneficial in a subject in need thereof, the method comprising administering to said subject miR-181 or a precursor thereof or expressing in a cell of said subject an exogenous polynucleotide encoding a miR-181 or a precursor thereof, thereby treating the medical condition.

### Claim 2 (depends on 1)

The method of claim 1, wherein said medical condition is selected from the group consisting of a seizure, a Huntington's disease, a schizophrenia, a fragile X syndrome, a generalized anxiety disorder, a memory impairment and a cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein said subject is a human subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein said miR-181 is as set forth in SEQ ID NO: 85-94.

### Claim 5 (depends on 1)

The method of claim 1, wherein said miR-181 comprises a modification selected from the group consisting of a modified backbone, a modified internucleoside linkage and a modified base.

### Claim 6 (depends on 5)

The method of claim 5, wherein said modification is selected from the group consisting of a phosphorothioate, a chiral phosphorothioate, a phosphorodithioate, a phosphotriester, an aminoalkyl phosphotriester, a methyl phosphonate, an alkyl phosphonate, a chiral phosphonate, a phosphinate, a phosphoramidate, an aminoalkylphosphoramidate, a thionophosphoramidate, a thionoalkylphosphonate, a thionoalkylphosphotriester, a boranophosphate, a peptide nucleic acid (PNA), a 2′-O-methoxyethyl, a 2′-O-methyl and a 2′-fluoro.

### Claim 7 (depends on 1)

The method of claim 1, wherein said miR-181 comprises a modification in both a sugar and an internucleoside linkage.

### Claim 8 (depends on 1)

The method of claim 1, wherein said cell is a neuroglia cell.

### Claim 9

An isolated cell comprising a nucleic acid construct expressing a miR-181 or a precursor thereof under a transcriptional control of a cis acting regulatory element.

### Claim 10 (depends on 9)

The isolated cell of claim 9, wherein said cell is a neuroglia cell.

### Claim 11 (depends on 9)

The isolated cell of claim 9, wherein said miR-181 is as set forth in SEQ ID NO: 85-94.

### Claim 12

A nucleic acid construct comprising a nucleic acid sequence encoding a miR-181 or a precursor thereof, said nucleic acid sequence being under a transcriptional control of a cis acting regulatory element.

### Claim 13 (depends on 12)

The nucleic acid construct of claim 12, wherein said cis acting regulatory element is active in a neuroglia cell or a cardiac cell.

### Claim 14 (depends on 12)

A pharmaceutical composition comprising the nucleic acid construct of claim 12 and a pharmaceutically acceptable carrier or diluent.

### Claim 15

A method of regulating an expression of a glutamate receptor gene in a neuroglia cell, the method comprising modulating an activity or expression of miR-181 or a precursor thereof in said neuroglia cell, thereby regulating the expression of the glutamate receptor gene.

### Claim 16 (depends on 15)

The method of claim 15, wherein said glutamate receptor gene is selected from the group consisting of glutamate receptor metabotropic 1 (Grm1), glutamate receptor ionotropic kainate 3 (Grik3), glutamate receptor metabotropic 5 (Grm5), glutamate receptor ionotropic kainate 2 (Grik2) and glutamate receptor metabotropic 7 (Grm7).
